JP2018529779A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529779A5
JP2018529779A5 JP2018536704A JP2018536704A JP2018529779A5 JP 2018529779 A5 JP2018529779 A5 JP 2018529779A5 JP 2018536704 A JP2018536704 A JP 2018536704A JP 2018536704 A JP2018536704 A JP 2018536704A JP 2018529779 A5 JP2018529779 A5 JP 2018529779A5
Authority
JP
Japan
Prior art keywords
milligrams
composition
therapeutically effective
effective amount
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018536704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529779A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/055206 external-priority patent/WO2017059451A1/en
Publication of JP2018529779A publication Critical patent/JP2018529779A/ja
Publication of JP2018529779A5 publication Critical patent/JP2018529779A5/ja
Priority to JP2021139287A priority Critical patent/JP2021183640A/ja
Withdrawn legal-status Critical Current

Links

JP2018536704A 2015-10-02 2016-10-03 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転 Withdrawn JP2018529779A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021139287A JP2021183640A (ja) 2015-10-02 2021-08-27 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562236702P 2015-10-02 2015-10-02
US62/236,702 2015-10-02
PCT/US2016/055206 WO2017059451A1 (en) 2015-10-02 2016-10-03 Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021139287A Division JP2021183640A (ja) 2015-10-02 2021-08-27 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転

Publications (2)

Publication Number Publication Date
JP2018529779A JP2018529779A (ja) 2018-10-11
JP2018529779A5 true JP2018529779A5 (cg-RX-API-DMAC10.html) 2019-11-14

Family

ID=58428002

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018536704A Withdrawn JP2018529779A (ja) 2015-10-02 2016-10-03 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転
JP2021139287A Pending JP2021183640A (ja) 2015-10-02 2021-08-27 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021139287A Pending JP2021183640A (ja) 2015-10-02 2021-08-27 活性化脂肪酸の治療有効量を使用する疾患の予防、処置および逆転

Country Status (17)

Country Link
US (3) US10537541B2 (cg-RX-API-DMAC10.html)
EP (1) EP3355879A4 (cg-RX-API-DMAC10.html)
JP (2) JP2018529779A (cg-RX-API-DMAC10.html)
KR (1) KR20180098222A (cg-RX-API-DMAC10.html)
CN (2) CN113440506A (cg-RX-API-DMAC10.html)
AU (2) AU2016331314A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018006687A2 (cg-RX-API-DMAC10.html)
CA (1) CA3000842A1 (cg-RX-API-DMAC10.html)
CL (1) CL2018000835A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018004576A2 (cg-RX-API-DMAC10.html)
CR (1) CR20180246A (cg-RX-API-DMAC10.html)
EA (1) EA201890859A1 (cg-RX-API-DMAC10.html)
HK (1) HK1259031A1 (cg-RX-API-DMAC10.html)
IL (2) IL297844A (cg-RX-API-DMAC10.html)
MX (1) MX2018004043A (cg-RX-API-DMAC10.html)
SG (1) SG10201913953UA (cg-RX-API-DMAC10.html)
WO (1) WO2017059451A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2280928T3 (en) * 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
CN113440506A (zh) * 2015-10-02 2021-09-28 康普莱克夏公司 使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病
BR112020024019A2 (pt) 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
CN111229120B (zh) * 2018-11-29 2022-01-07 中国石油化工股份有限公司 含脂肪酸型表面活性剂的混合体系及其制备方法
CN111229117B (zh) * 2018-11-29 2022-01-04 中国石油化工股份有限公司 含脂肪酸型表面活性剂的混合体系及其制备方法
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
CN110157792A (zh) * 2019-04-22 2019-08-23 中山大学孙逸仙纪念医院 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用
WO2021242758A1 (en) * 2020-05-26 2021-12-02 Imara Inc. Improved nitro-fatty acid oral dose regimens
WO2023014748A1 (en) * 2021-08-03 2023-02-09 Imara Inc. Nitrated fatty acids for the treatment of sickle cell disorders

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB587992A (en) 1944-12-11 1947-05-12 Charles William Scaife Improvements in and relating to the production of organic nitrogen compounds
US3578687A (en) 1968-01-30 1971-05-11 Texaco Inc Process for producing 4-nitroalkanoic acids
US3819561A (en) 1970-10-23 1974-06-25 Aerojet General Co Wetting agents for non-aqueous dispersions
JPS5313608B2 (cg-RX-API-DMAC10.html) 1972-06-16 1978-05-11
JPS5318013B2 (cg-RX-API-DMAC10.html) 1973-03-19 1978-06-13
US4599430A (en) 1981-12-21 1986-07-08 The Standard Oil Company Nitrogenation of hydrocarbons, including the production of maleimide
JPS62132804A (ja) 1985-12-05 1987-06-16 Aguro Kanesho Kk 植物生長調節剤
US5412137A (en) 1993-06-07 1995-05-02 Sandoz Ltd. Process for preparing phosphinyloxy propanaminium inner salt derivatives
CN1088058C (zh) 1994-10-13 2002-07-24 肽技术有限公司 经修饰的多不饱和脂肪酸
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
GB9618420D0 (en) 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
JP4309045B2 (ja) 1997-10-30 2009-08-05 森下仁丹株式会社 不飽和脂肪酸またはその誘導体を内容物とするカプセル製剤およびその製造法
US6262029B1 (en) 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
US6459003B1 (en) 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
AU5319499A (en) 1999-07-22 2001-02-13 Ivan L. Cameron Fatty acids to minimize cancer therapy side effects
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AUPQ291499A0 (en) 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
US6346231B1 (en) 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
US20010037598A1 (en) 1999-12-14 2001-11-08 Suppes Galen J. Process for producing cetane improvers from triglycerides
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
AR030416A1 (es) 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
CN1232480C (zh) 2000-06-28 2005-12-21 萨宝集团公司 制备硝基烯烃的方法
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
DK1900364T3 (da) 2001-04-18 2014-01-13 Prometic Biosciences Inc Fedtsyrer, glycerider og analoger med medium kædelængde som neutrofile overlevelses- og aktiveringsfaktorer
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US20040176451A1 (en) 2001-06-18 2004-09-09 Tadakazu Tamai Pparg agonistic medicinal compositions
JP2005501096A (ja) 2001-08-17 2005-01-13 ユニヴァーシティ オブ ピッツバーグ 肥満、代謝症候群、糖尿病、血管障害及び腎臓疾患を治療又は予防するエストラジオールメタボライトの投与
GB0123961D0 (en) 2001-10-05 2001-11-28 Astrazeneca Ab Process and intermediates
CA2465117C (en) 2001-11-06 2012-01-03 Brigham And Women's Hospital, Inc. Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
EP1558237A4 (en) 2002-09-27 2007-01-17 Martek Biosciences Corp IMPROVED BLOOD SUGAR CONTROL F RPRU-DIABETES AND / OR DIABETES TYPE II USING DOCOSAHEXAENSURE
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2005016864A1 (en) 2003-07-29 2005-02-24 The Arizona Disease Control Research Commission Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
US20050136103A1 (en) 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
JP2007522118A (ja) 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
WO2005110396A2 (en) 2004-04-28 2005-11-24 Uab Research Foundation Nitrated lipids and methods of making and using thereof
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
EP1772149A1 (en) 2004-07-27 2007-04-11 Kowa Company. Ltd. Drug for prevention or treatment of diabetes
CA2588166A1 (en) 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US20070032420A1 (en) 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
WO2008008767A2 (en) 2006-07-14 2008-01-17 Cedars-Sinai Medical Center Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer
BRPI0714562A2 (pt) 2006-07-19 2013-04-02 Resolvyx Pharmaceuticals Inc composiÇÕes e mÉtodos para o tratamento de mucosites
EP2120920A4 (en) 2007-02-20 2011-06-15 Martek Biosciences Corp OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
EP2679224A1 (en) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Nitro oleic acid modulation of type II diabetes
EP2207543A2 (en) 2007-09-14 2010-07-21 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function
US20110092594A1 (en) 2008-04-18 2011-04-21 Tianxin Yang Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
DK2280928T3 (en) 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
WO2009149496A1 (en) 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
CN102099024B (zh) 2008-06-19 2015-11-25 犹他大学研究基金会 硝化脂质在毒性医疗疗法的副作用的治疗上的用途
ES2622559T3 (es) 2008-07-29 2017-07-06 Nerviano Medical Sciences S.R.L. Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
JP2012513774A (ja) 2008-12-31 2012-06-21 ニトロメガ コーポレーション ニトロ脂肪酸を含有する栄養補助物
US8937194B2 (en) * 2008-12-31 2015-01-20 Nitromega Corp. Topical compositions containing nitro fatty acids
US20100286271A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Nitro-alkyl Compound Compositions
US20100286257A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
US20100286272A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
KR20120046754A (ko) 2009-07-29 2012-05-10 페노미넘 디스커버리스 인코포레이티드 히드록시 지방산 화합물 및 질병 치료 및 진단을 위한 그의 용도
CA2769624C (en) 2009-07-31 2018-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Electrophilic fatty acid derivatives as anti-inflammatory agents
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
US20130005730A1 (en) 2009-11-09 2013-01-03 Piaoyang Sun Novel 1,3-oxazolidine compounds and their use as renin inhibitors
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
WO2011113507A2 (en) * 2010-03-15 2011-09-22 Ulrich Dietz Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
BR112012027915A2 (pt) 2010-05-13 2018-10-23 Nitromega Corp nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
EP2590643A4 (en) 2010-06-28 2014-01-01 Complexa Inc MEDICINAL PRODUCT MADE FROM SEVERAL INGREDIENTS FOR THE TREATMENT OF DIABETES
EP2744491B1 (en) * 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
US9271952B2 (en) 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
DE102012008730A1 (de) * 2011-12-02 2013-06-06 Dr. Budz GmbH Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
WO2013116753A1 (en) 2012-02-03 2013-08-08 University Of Pittsburgh-Of The Commonwelth System Of Higher Education Fatty acids as anti-inflammatory agents
US20140271844A1 (en) * 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
WO2014183108A1 (en) 2013-05-10 2014-11-13 Nitromega Corp. Nutritional or dietary supplements containing fatty acids and nitrite
WO2014204872A2 (en) 2013-06-14 2014-12-24 Complexa, Inc. Composition and method for inhibition of pkng from mycobacterium tuberculosis
WO2015073527A1 (en) 2013-11-12 2015-05-21 Complexa, Inc. Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
US20180092948A1 (en) * 2015-04-02 2018-04-05 Aobiome Llc Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria
CN113440506A (zh) * 2015-10-02 2021-09-28 康普莱克夏公司 使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病

Similar Documents

Publication Publication Date Title
IL297844A (en) Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
JP2023002662A5 (cg-RX-API-DMAC10.html)
EP3419624B1 (en) Methods for using fxr agonists
JP2020073546A5 (cg-RX-API-DMAC10.html)
JP2023504415A5 (cg-RX-API-DMAC10.html)
JP2020502250A5 (cg-RX-API-DMAC10.html)
JP2018518537A5 (cg-RX-API-DMAC10.html)
JP2020535225A5 (cg-RX-API-DMAC10.html)
JP2019515884A5 (cg-RX-API-DMAC10.html)
JP2013521303A5 (cg-RX-API-DMAC10.html)
JP7860961B2 (ja) 原発性胆汁性胆管炎の治療のための組成物及び方法
JP2017508817A5 (cg-RX-API-DMAC10.html)
JP2008533127A5 (cg-RX-API-DMAC10.html)
CN116615217A (zh) 炎症性疾病和/或疼痛性疾病的预防或治疗药
JP2015508068A5 (cg-RX-API-DMAC10.html)
JP7523691B2 (ja) 急性膵炎を予防及び治療するための薬物の製造におけるノルハルマンの使用
JP6878596B2 (ja) Ｆｘｒアゴニストの組合せ
Chave et al. Henoch‐Schönlein purpura following hepatitis B vaccination
WO2019053582A1 (en) COMBINATIONS HAVING FXR AGONISTS
FI3706724T3 (fi) Suun kautta otettavia rifamysiini sv -koostumuksia
JP2019507786A5 (cg-RX-API-DMAC10.html)
KR20210110407A (ko) Fxr 작용제의 신규 요법
Christopoulou et al. Hyponatremia in patients with heart failure beyond the neurohormonal activation associated with reduced cardiac output: A holistic approach
JP2019509309A5 (cg-RX-API-DMAC10.html)
Buchanan-Peart et al. Novel therapies in primary biliary cholangitis: what is in the pipeline?